Brokers Issue Forecasts for ACAD Q1 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of ACADIA Pharmaceuticals in a research note issued on Thursday, February 27th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical company will earn $0.04 per share for the quarter. The consensus estimate for ACADIA Pharmaceuticals' current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals' Q2 2025 earnings at $0.17 EPS, Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.60 EPS, FY2027 earnings at $1.25 EPS, FY2028 earnings at $2.00 EPS and FY2029 earnings at $2.45 EPS.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reiterated a "buy" rating and issued a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, February 11th. They issued a "hold" rating and a $22.00 price objective for the company. Guggenheim downgraded shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the company from $23.00 to $20.00 in a research report on Friday, January 3rd. StockNews.com cut shares of ACADIA Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $28.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, February 27th. Nine investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, ACADIA Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $24.00.

Remove Ads

ACADIA Pharmaceuticals Trading Down 2.6 %

Shares of NASDAQ ACAD traded down $0.47 during trading hours on Monday, reaching $17.61. The stock had a trading volume of 1,650,960 shares, compared to its average volume of 2,678,850. ACADIA Pharmaceuticals has a 52-week low of $14.15 and a 52-week high of $24.27. The firm has a market cap of $2.93 billion, a price-to-earnings ratio of 22.58 and a beta of 0.37. The business's fifty day moving average price is $18.49 and its two-hundred day moving average price is $16.91.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. purchased a new position in ACADIA Pharmaceuticals during the 4th quarter worth approximately $40,935,000. SG Americas Securities LLC raised its holdings in shares of ACADIA Pharmaceuticals by 380.3% during the fourth quarter. SG Americas Securities LLC now owns 2,483,731 shares of the biopharmaceutical company's stock worth $45,576,000 after purchasing an additional 1,966,607 shares during the last quarter. Norges Bank acquired a new position in ACADIA Pharmaceuticals during the fourth quarter valued at $25,555,000. Renaissance Technologies LLC boosted its holdings in ACADIA Pharmaceuticals by 204.2% in the fourth quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company's stock valued at $22,507,000 after purchasing an additional 823,333 shares during the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of ACADIA Pharmaceuticals by 160.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,263,200 shares of the biopharmaceutical company's stock valued at $23,180,000 after buying an additional 778,900 shares during the last quarter. Institutional investors and hedge funds own 96.71% of the company's stock.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, Director Elizabeth A. Garofalo sold 4,919 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $18.23, for a total transaction of $89,673.37. Following the completion of the sale, the director now owns 17,595 shares of the company's stock, valued at approximately $320,756.85. The trade was a 21.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 6,167 shares of company stock valued at $114,583. Insiders own 28.30% of the company's stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.